Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Human vaccines: news.

Riedmann EM.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1550-3. doi: 10.4161/hv.22753. Epub 2012 Nov 1. No abstract available.

2.

Human vaccines & immunotherapeutics: News.

Riedmann EM.

Hum Vaccin Immunother. 2014;10(5):1139-42. doi: 10.4161/hv.29344. No abstract available.

3.

Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009.

[No authors listed]

Wkly Epidemiol Rec. 2009 Aug 7;84(32):325-32. English, French. No abstract available.

4.

Global Advisory Committee on Vaccine Safety,12–13 June 2013.

[No authors listed]

Wkly Epidemiol Rec. 2013 Jul 19;88(29):301-12. English, French. No abstract available.

5.

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.

Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G; HPV-010 Study Group..

Hum Vaccin. 2009 Oct;5(10):705-19. Epub 2009 Oct 14.

PMID:
19684472
6.

Quadrivalent human papillomavirus recombinant vaccine: the first vaccine for cervical cancers.

Sharma R, Sharma CL.

J Cancer Res Ther. 2007 Apr-Jun;3(2):92-5. Review.

7.

Human papillomavirus vaccine for cancer prevention.

Finn OJ, Edwards RP.

N Engl J Med. 2009 Nov 5;361(19):1899-901. doi: 10.1056/NEJMe0907480. No abstract available.

PMID:
19890134
8.

Vaccines and immunizations.

[No authors listed]

J Pract Nurs. 2011 Fall;61(3):14-20. No abstract available.

PMID:
22479968
9.

[Vaccines for precancer and cancer of uterine cervix. I. Prophylactic HPV vaccines].

Zlatkov V, Kostova P.

Akush Ginekol (Sofiia). 2007;46(7):27-31. Review. Bulgarian.

PMID:
18333418
10.

Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.

Pomfret TC, Gagnon JM Jr, Gilchrist AT.

J Clin Pharm Ther. 2011 Feb;36(1):1-9. doi: 10.1111/j.1365-2710.2009.01150.x. Review.

PMID:
21198715
11.

Edward Jenner Institute for Vaccine Research--third international meeting: 12-16 April 2003, Oxford, UK.

Williams NA.

IDrugs. 2003 Jun;6(6):527-30. No abstract available.

PMID:
12861977
12.

Opening Fronts in HIV Vaccine Development: Tracking the development of broadly neutralizing antibodies.

Gruell H, Klein F.

Nat Med. 2014 May;20(5):478-9. doi: 10.1038/nm.3567. No abstract available.

PMID:
24804756
13.

Therapeutic human papillomavirus vaccines: current clinical trials and future directions.

Hung CF, Ma B, Monie A, Tsen SW, Wu TC.

Expert Opin Biol Ther. 2008 Apr;8(4):421-39. doi: 10.1517/14712598.8.4.421 . Review.

14.

[Papillomavirus vaccines now allowed--ethical and logistical considerations].

Höpfl R.

J Dtsch Dermatol Ges. 2007 May;5(5):349-52. German. No abstract available.

PMID:
17451379
15.

Human papillomavirus vaccines for the treatment of cervical cancer.

Sin JI.

Expert Rev Vaccines. 2006 Dec;5(6):783-92. Review.

PMID:
17184217
16.

[Vaccines for precancer and cancer of the uterine cervix. II. Therapeutic HPV vaccines].

Kostova P, Zlatkov V.

Akush Ginekol (Sofiia). 2007;46(8):31-5. Bulgarian.

PMID:
18642554
17.

[Progress of integrative medicine, human papillomavirus vaccine and molecular targeted therapy for cervical cancer].

Cho CS.

Zhong Xi Yi Jie He Xue Bao. 2008 Feb;6(2):203-8. Review. Chinese. No abstract available.

18.

Human papillomavirus (HPV) and HPV-associated tumour vaccines.

Bubeník J.

Folia Biol (Praha). 2006;52(1-2):45-6. No abstract available.

19.

[Influenza, rotaviruses, HPV: why you should promote these vaccinations].

Meissner T.

MMW Fortschr Med. 2012 Feb 9;154(2):22. German. No abstract available.

PMID:
22352242
20.

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.

Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ.

N Engl J Med. 2009 Nov 5;361(19):1838-47. doi: 10.1056/NEJMoa0810097.

Supplemental Content

Support Center